CBER’s “Boutique” Role: Fitting In Oncology Center of Excellence
This article was originally published in RPM Report
FDA is close to announcing a new “Oncology Center of Excellence” to consolidate drug, biologic and device review functions in cancer. In the run up to the announcement, CBER has been stressing the need to preserve its culture and experience with novel manufacturing techniques.
Register for our free email digests: